Core Insights - NeuroPace, Inc. (NPCE) achieved $100 million in revenue for 2025, reflecting a 25% year-over-year growth, with a focus on the core RNS System as non-core revenue diminishes [2][10] - The company anticipates continued growth in its adult focal RNS franchise, projecting at least 20% growth for 2026, aligning with its long-term strategy [3][10] - The stock is expected to perform in line with the market, emphasizing the importance of execution, valuation, and catalysts rather than merely identifying peak performance [3] Revenue and Business Transition - The 2025 revenue growth was supported by a shift towards the core RNS business, with DIXI Medical contributing approximately 16% of revenue, which will cease after inventory sell-through by the end of 2025 [4][11] - The transition to a "pure-play" RNS model is expected to enhance profitability and operational focus, as DIXI revenue will no longer be recorded post-2025 [11][12] Operational Growth and Market Dynamics - Management highlights the expansion of growth channels beyond Level 4 comprehensive epilepsy centers, which is crucial for accelerating procedure-based adoption [5] - Medicare's reimbursement updates effective January 1, 2026, significantly increase hospital and physician payments for RNS procedures, which could enhance adoption and procedure growth [13][14] Financial Metrics and Valuation - NPCE trades at approximately 4.57x forward 12-month sales per share, above the Zacks sub-industry average of 4.11x and the Medical sector at 2.28x, but below the S&P 500 at 5.06x [6] - The company’s gross margin improved to 77.4% in Q4 2025, with RNS gross margin at 80.5%, and is expected to reach 81.5%–82.5% in 2026 [12] Near-Term Challenges - The company anticipates adjusted EBITDA losses between $9 million to $11 million in 2026, with operating expenses projected at $90 million to $92 million, primarily in the first half of the year [15] - Revenue growth is expected to be moderated in the first half of 2026, with guidance of $21 million to $22 million for Q1, potentially impacting investor sentiment [16] Investment Framework - The investment outlook suggests a focus on whether fundamentals can improve sufficiently to justify the current premium valuation compared to historical sales multiples [17]

Core Insights - NeurAxis, Inc. has announced significant new medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, from a major national health insurer, expanding its coverage to approximately 100 million lives across multiple states [1][3] Company Overview - NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in both children and adults [4] - The company's proprietary technology, IB-Stim, is FDA-cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS) and functional dyspepsia (FD) in patients aged 8 years and older [2][4] Product Details - IB-Stim is a non-invasive device that stimulates cranial nerve bundles in the ear to regulate pain signaling between the gut and the brain, addressing a significant unmet medical need in pediatric patients [2] - Currently, there are no FDA-approved drug therapies for pediatric patients with abdominal pain related to functional dyspepsia, making IB-Stim a unique solution in this market [2] Market Position and Future Outlook - The CEO of NeurAxis expressed optimism about securing additional coverage from large national insurers, highlighting the growing recognition of IB-Stim as an evidence-based therapy for pediatric gastrointestinal disorders [3] - With a Category I CPT code effective January 1, 2026, and incorporation into leading national society clinical practice guidelines, NeurAxis is positioned for significant revenue growth and margin expansion [3]

Company Overview - NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in both children and adults [4] - The company is advancing its proprietary IB-Stim™ therapy, which utilizes Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, and is FDA cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 8-21 [4] - NeurAxis is conducting additional clinical trials of PENFS for various pediatric and adult conditions with significant unmet healthcare needs [4] Upcoming Events - NeurAxis will participate in the Lytham Partners Spring 2025 Investor Conference, with a webcast presentation scheduled for May 29, 2025, at 9:30 a.m. ET [1][2] - The webcast will be accessible via the conference homepage and will be available for replay after the event [2] - Management will also engage in virtual one-on-one meetings with investors during the conference [3]